Regeneron's purchase is still subject to court ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Regeneron Pharma is currently 0.35% higher at $596.39 on Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. As of May 6, 2025, the average one-year price target for ...

Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on oncology drug linvoseltamab. LINKER-MM2 is a phase Ib, open-label clinical ...

Source: Regeneron Pharmaceuticals, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our ...

The projected annual revenue for Regeneron Pharmaceuticals is 14,197MM ... of the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial data ...

Regeneron Pharmaceuticals (NASDAQ:REGN) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/20/25, Regeneron Pharmaceuticals, Inc. (Symbol: REGN), PROG Holdings Inc (Symbol: PRG), and Prudential Financial Inc (Symbol ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals ... and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of ...

There are 2,406 funds or institutions reporting positions in Regeneron Pharmaceuticals ... author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...